600 to 900 UK Dravet patients remain inadequately controlled on CBD plus fenfluramine combined, and a cardiac-monitoring-free profile is worth real NHS money.

Cannabidiol (Epidiolex, Jazz) and fenfluramine (Fintepla, UCB) are both NICE-commissioned, TA614 and TA808 respectively, and together define the UK Dravet standard of care: of an estimated 2,000-2,500 UK Dravet patients, 1,500-2,000 are on CBD and 400-600 are on the CBD-plus-fenfluramine combination. But combination therapy does not resolve the disease for everyone. An estimated 600-900 UK patients fail to achieve a 50% or greater seizure reduction on that combined background, concentrated at 6-8 NHS specialist paediatric epilepsy centres. This refractory cohort, not the broader Dravet population, is the addressable NICE submission target for any new entrant, and the trial comparator must be the combined background, not monotherapy.

Fenfluramine's NICE commissioning carries a mandatory cardiac-monitoring requirement, echocardiography at initiation, 3 and 6 months, then annually, and NHS paediatric echo waiting times of 4-12 weeks mean an estimated 15-25% of NHS-eligible Dravet patients are not receiving fenfluramine due to monitoring-capacity friction rather than clinical ineligibility. A new Dravet agent without a cardiac-monitoring requirement removes both a clinical access barrier and a real NHS cost: each echocardiogram runs £200-400, and the monitoring schedule adds £800-2,400 per patient a year that a REMS-free profile avoids outright. Soticlestat (Takeda/Ovid), with positive Phase 3 ELEKTRA data and no cardiac-monitoring requirement, is the clearest UK competitive benchmark, expected to file with the MHRA in 2025.

Soticlestat's near-identical timeline puts it on a collision course for the same patients.

Five questions this report answers:

Q1 - What evidence and comparator design does NICE require given CBD and fenfluramine are commissioned?

Q2 - How large is the UK refractory Dravet population, and how is it identified?

Q3 - What is the soticlestat competitive timeline and WAC/PAS design that clears NICE's bar?

Q4 - What deliverable formats come with a commissioned UK Dravet launch readiness assessment?

Q5 - What must a pre-launch Dravet syndrome asset prove to succeed in the UK?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#DravetSyndrome #Epilepsy #NICE #UKMarketAccess #RareDisease #LaunchReadiness

Live report page:  https://axlrx.ai/dravet-syndrome/uk/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/